dsm-firmenich is proud to announce its strategic partnership with Bod Science, an Australian-based pioneer in medical cannabis. The collaboration follows promising preliminary findings from Bod Science’s Phase IIb clinical trial, demonstrating the efficacy of a cannabidiol (CBD) formulation in alleviating insomnia symptoms and will see dsm-firmenich’s high quality GMP CBD active pharmaceutical ingredient (API) play a crucial role in advancing the next phase of commercialization. Bod Science expects to announce the full results of the trial, including the secondary end points of the study, assessing the efficacy of the formulation on anxiety, stress and wake-after-sleep-onset (WASO) in the coming month. Together, the companies are positioned to make a significant impact with one of the world’s first CBD-based medicines for insomnia.
dsm-firmenich strengthens status as cannabinoid expert in the pharmaceutical market
The dsm-firmenich and Bod Science partnership is a significant milestone in the field of cannabinoid research and development, and a major step forward as companies strive to bring a CBD product to market in the region.
Athanasia Kanli, Global Market Development Manager Pharma at dsm-firmenich comments: “Recent changes by the Therapeutic Goods Administration (TGA) of Australia provide a pathway to register a low dose CBD product for specific need states, such as insomnia under Schedule 3, which permits sale over the counter (OTC) in pharmacies. This offers an opportunity for Bod Science to be a frontrunner in the development of its CBD-based formulation for insomnia. Just like us, Bod Science has a passion for advancing the science in the cannabinoid space and recognizes the therapeutic possibilities of these unique ingredients in the Pharma portfolio of dsm-firmenich. The collaboration holds exciting potential far beyond our ingredient expertise, and we can’t wait for the opportunities it will unlock. We are proud to be partnering with Bod for the benefit of patients.”
Promising future for CBD in insomnia treatment
Insomnia is a prevalent global concern that profoundly impacts individuals’ quality of life and health. The preliminary findings of Bod Science’s Phase IIb trial, involving 208 participants, demonstrated that 100 mg CBD treatment showed statistical significance over placebo for the primary endpoint of relief from short-term insomnia with a p-value of 0.04 in the per protocol group.
Jo Patterson, CEO at Bod Science, adds: “These results pave the way for a us to apply to the TGA to register our CBD-based treatment for insomnia, so that it may be available to patients in Australia without a prescription. We are on the cusp of achieving an important milestone and are thrilled to be on this journey with dsm-firmenich – a renowned global pioneer in the cannabinoid market. Our Phase IIb clinical trial is the final step in R&D for the product. Collaborating with dsm-firmenich was an obvious choice for us, not just for its GMP CBD API, but for its deep understanding of the regulatory landscape, state-of-the-art technical expertise and end-to-end capabilities in the field.”
Innovation platform for cannabinoid-based drug development
Together, dsm-firmenich and Brains Bioceutical, science-led pioneer of cannabinoid solutions and GMP certified CBD API manufacturer, offer a unique end-to-end innovation platform designed to unlock customized cannabinoid therapeutics – with a spotlight on exploring the science behind cannabinoids in promising indications, including pain management, stress and anxiety. The supply agreement and partnership with Bod Science will see the launch of a novel CBD pharmaceutical in soft gel format, utilizing a patent protected encapsulation technology.
For more information, or to find out how dsm-firmenich is helping to bring purpose-led cannabinoid pharmaceuticals to market visit: dsm-firmenich Pharma Solutions.
About dsm-firmenich
As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss-Dutch company, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life™ every day, everywhere, for billions of people.
For more information
Media e-mail: celine.zuber@dsm-firmenich.com
Issuing agency e-mail: dsmhnc@bdb.co.uk
Investors e-mail: investors@dsm-firmenich.com
Forward-looking statements
This press release may contain forward-looking statements with respect to dsm-firmenich’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. The English language version of this press release prevails over other language versions.
